Is Moderna Stock a Buy?
Share prices of (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S 500 index. The biotech, renowned for its pioneering development of vaccines based on messenger RNA (mRNA), has struggled to manage weak sales of COVID-19 vaccine and sluggish market adoption of its new shot for respiratory syncytial virus (RSV). The stock sell-off has continued into 2025, with shares already falling 18% year to date, on the heels of the company slashing its full-year revenue guidance.
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound.
Let's discuss the pros and cons of buying Moderna stock.
Source Fool.com
Moderna Inc. Stock
Based on 8 Buy predictions and 9 Sell predictions the sentiment towards Moderna Inc. is rather balanced.
A target price of 21 € results in a potential of -53.68% which would mean heavy losses compared to the current price of 45.34 € for Moderna Inc..
